<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Erythrodermic psoriasis in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Erythrodermic psoriasis in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Erythrodermic psoriasis in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jason E Hawkes, MD, MS, FAAD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristina Callis Duffin, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey Callen, MD, FACP, FAAD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Abena O Ofori, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 02, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2642612232">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Erythrodermic psoriasis is an uncommon, severe variant of psoriasis that is characterized by widespread erythema of the skin. Patients with this psoriasis subtype typically present with erythema involving more than 75 percent of the body surface area and associated scale, pustules, or exfoliation of the skin  (
         <a class="graphic graphic_picture graphicRef111552 graphicRef111553 graphicRef111554" href="/z/d/graphic/111552.html" rel="external">
          picture 1A-C
         </a>
         ).
        </p>
        <p>
         Recognition of this potentially life-threatening form of psoriasis is imperative. A detailed history and thorough evaluation of the patient are necessary to establish a diagnosis and rule out conditions that closely mimic erythrodermic psoriasis. (See
         <a class="medical medical_review" href="/z/d/html/13659.html" rel="external">
          "Erythroderma in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/89273.html" rel="external">
          "Erythroderma in children"
         </a>
         .)
        </p>
        <p>
         The clinical manifestations, diagnosis, and management of erythrodermic psoriasis will be discussed here. Other variants of psoriasis are reviewed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5664.html" rel="external">
          "Psoriasis: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">
          "Treatment of psoriasis in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/89271.html" rel="external">
          "Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/93554.html" rel="external">
          "Pustular psoriasis: Management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15280.html" rel="external">
          "Guttate psoriasis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/96391.html" rel="external">
          "Nail psoriasis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3618932281">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Psoriasis is estimated to affect approximately 3 percent of the adult population in the United States [
         <a href="#rid1">
          1
         </a>
         ]. There are several psoriasis subtypes, including chronic plaque, psoriatic arthritis, inverse, guttate, pustular, and erythrodermic variants. Erythrodermic psoriasis is the least common psoriasis subtype and occurs in less than 3 percent of patients [
         <a href="#rid2">
          2
         </a>
         ]. Some experts have suggested that the distinction between generalized pustular and erythrodermic psoriasis is arbitrary given their frequent co-occurrence and overlapping clinical features. (See
         <a class="medical medical_review" href="/z/d/html/89271.html" rel="external">
          "Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="local">
          'Clinical manifestations'
         </a>
         below.)
        </p>
        <p>
         The age of onset of erythroderma is highly variable [
         <a href="#rid3">
          3,4
         </a>
         ]. In a series of 50 patients with erythrodermic psoriasis, the average age of onset was 48 years [
         <a href="#rid3">
          3
         </a>
         ]. There appears to be a slight predilection for males in adulthood [
         <a href="#rid3">
          3
         </a>
         ]; however, detailed epidemiologic data for this condition are limited due to its rarity.
        </p>
        <p class="headingAnchor" id="H1729190946">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Similar to other psoriasis variants, erythrodermic psoriasis is the result of a complex interaction between the skin, environmental and genetic factors, and the immune system. Few studies have examined the molecular mechanisms driving the development of this disease variant, and the immunopathogenesis is not fully understood. (See
         <a class="medical medical_review" href="/z/d/html/15277.html" rel="external">
          "Pathophysiology of plaque psoriasis"
         </a>
         .)
        </p>
        <p>
         A study evaluating the gene expression profiles of involved skin from patients with chronic plaque, inverse, and erythrodermic variants of psoriasis found similarities among these variants, suggesting a shared pathway for disease development [
         <a href="#rid5">
          5
         </a>
         ]. More than 95 percent of the differentially expressed genes in erythrodermic psoriasis were also differentially expressed in plaque psoriasis. Differential expression of genes relating to the interleukin-17A signaling pathway accounted for the greatest amount of similarity between plaque and erythrodermic psoriasis. However, differences in the T helper cell (Th) populations and inflammatory cytokines isolated from the blood of patients with erythrodermic psoriasis compared with plaque psoriasis have also been described [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
         A study of 63 Chinese patients with erythrodermic psoriasis demonstrated that the prevalence of the primary plaque psoriasis genetic variant, HLA-Cw0602, may be less common in erythrodermic psoriasis patients (4 versus 16 percent in Chinese plaque psoriasis patients). The most common variants were HLA-C*0102 (34 percent), followed by HLA-C*0702 (18 percent) [
         <a href="#rid8">
          8
         </a>
         ]. A mutation in
         <em>
          CARD14
         </em>
         , a known variant associated with pustular psoriasis, has also been detected in a pedigree with erythrodermic psoriasis [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         A shared pathway for erythroderma is suggested based upon a study that compared the immunophenotypic features of psoriasis and atopic dermatitis. Although the study found significant differences in the Th1:Th2 ratio between chronic psoriasis and chronic atopic dermatitis, no differences in the Th1, Th2, Th17, and Th22 cell populations were observed between erythrodermic psoriasis and erythrodermic atopic dermatitis [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2712997611">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major risk factors for erythrodermic psoriasis are a personal or family history of psoriasis, medication exposure (particularly systemic glucocorticoids), and medical illness:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          History of psoriasis
         </strong>
         – The majority of patients with erythrodermic psoriasis have a known personal or family history of psoriasis [
         <a href="#rid3">
          3
         </a>
         ]. Importantly, erythrodermic psoriasis may be the initial presentation of psoriasis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medications
         </strong>
         – The most important medication-associated trigger of erythrodermic psoriasis is treatment with systemic glucocorticoids or the abrupt withdrawal of systemic antipsoriatic medications such as
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         and
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         [
         <a href="#rid3">
          3,11
         </a>
         ]. Erythrodermic psoriasis can also be triggered by an administration of antipsoriatic medications, such as oral and topical retinoids (eg,
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         and
         <a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">
          tazarotene
         </a>
         ), methotrexate, cyclosporine, and overuse of topical corticosteroids (ie, use of more than 60 g per week of a high-potency topical corticosteroid) [
         <a href="#rid3">
          3
         </a>
         ]. Other medications associated with the development of erythrodermic psoriasis include tumor necrosis factor (TNF)-alpha inhibitors [
         <a href="#rid12">
          12,13
         </a>
         ],
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         [
         <a href="#rid14">
          14
         </a>
         ],
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         [
         <a href="#rid15">
          15
         </a>
         ], and pegylated interferon-alpha with
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection
         </strong>
         – Infections have been proposed as triggers for erythrodermic psoriasis. Patients with human immunodeficiency virus (HIV) infection have increased risk for erythrodermic psoriasis. The severity of psoriasis in HIV-infected patients positively correlates with the level of immunosuppression [
         <a href="#rid17">
          17
         </a>
         ]. Cases of erythrodermic psoriasis following coronavirus disease 2019 (COVID-19) infection [
         <a href="#rid18">
          18
         </a>
         ] and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination [
         <a href="#rid19">
          19,20
         </a>
         ] have been reported.
        </p>
        <p>
        </p>
        <p>
         Other factors that have been reported to trigger erythrodermic psoriasis include burns from phototherapy or photochemotherapy treatments [
         <a href="#rid3">
          3
         </a>
         ], stress [
         <a href="#rid3">
          3,21
         </a>
         ], alcohol consumption [
         <a href="#rid3">
          3
         </a>
         ], and application of topical irritants (eg,
         <a class="drug drug_general" data-topicid="8878" href="/z/d/drug information/8878.html" rel="external">
          coal tar
         </a>
         , dithranol, and thiuram-containing rubber gloves ) [
         <a href="#rid3">
          3,22,23
         </a>
         ]. Case reports suggest that hypocalcemia can trigger erythrodermic [
         <a href="#rid24">
          24
         </a>
         ] or pustular forms of psoriasis [
         <a href="#rid25">
          25,26
         </a>
         ]. However, the relationship between psoriasis and serum calcium levels is unclear.
        </p>
        <p class="headingAnchor" id="H187654520">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The hallmark of erythrodermic psoriasis is the development of widespread, confluent erythema of the skin  (
         <a class="graphic graphic_picture graphicRef111552 graphicRef111553 graphicRef111554" href="/z/d/graphic/111552.html" rel="external">
          picture 1A-C
         </a>
         ). Erythema may develop rapidly (eg, over several days) or in a more gradual manner (eg, over several weeks). The percentage of body surface area involvement required for a patient to be considered erythrodermic is ambiguous; definitions range from 75 to more than 90 percent [
         <a href="#rid3">
          3,27
         </a>
         ]. Scaling and exfoliation of the skin is common and usually develops several days after the onset of erythroderma  (
         <a class="graphic graphic_picture graphicRef111557 graphicRef111558 graphicRef112110 graphicRef112111" href="/z/d/graphic/111557.html" rel="external">
          picture 2A-D
         </a>
         ). There may be associated palmoplantar keratoderma.
        </p>
        <p>
         The skin is often painful and/or pruritic, particularly in areas with prominent scaling [
         <a href="#rid28">
          28
         </a>
         ]. Photosensitivity also may be present. Associated extracutaneous findings may include fever, chills, malaise, tachycardia, arthralgias, and lymphadenopathy [
         <a href="#rid3">
          3
         </a>
         ]. Laboratory abnormalities may include leukocytosis, eosinophilia, and anemia [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Erythrodermic psoriasis often exhibits pustules, similar to those occurring in pustular psoriasis  (
         <a class="graphic graphic_picture graphicRef111555 graphicRef111556" href="/z/d/graphic/111555.html" rel="external">
          picture 3A-B
         </a>
         ). The pustules commonly involve the extremities. In a series of 50 patients with erythrodermic psoriasis, 14 patients (28 percent) had pustules [
         <a href="#rid3">
          3
         </a>
         ]. Generalized pustular involvement has been reported and is representative of the overlap between erythrodermic psoriasis and generalized pustular psoriasis. There are no clinical features that reliably distinguish erythrodermic psoriasis with pustules from generalized pustular psoriasis. (See
         <a class="medical medical_review" href="/z/d/html/89271.html" rel="external">
          "Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
         Associated nail disorders are common and range from pitting of the nail plate to more prominent nail dystrophy and/or separation of the nail from the nail bed (onycholysis). In a series of 50 patients with erythrodermic psoriasis, 39 (78 percent) had nail disease [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13682.html" rel="external">
          "Overview of nail disorders", section on 'Surface texture abnormalities'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13682.html" rel="external">
          "Overview of nail disorders", section on 'Defects of nail plate attachment/nail shedding'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H891387188">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A diagnosis of erythrodermic psoriasis should be considered in all patients presenting with erythroderma (ie, erythema involving at least 75 percent of the body surface area). The diagnosis is made based upon the recognition of features of psoriasis in the patient history, physical examination, and/or skin biopsy and the absence of features indicative of other causes of erythroderma. (See
         <a class="medical medical_review" href="/z/d/html/13659.html" rel="external">
          "Erythroderma in adults", section on 'Determining the underlying cause'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2812973537">
         <span class="h2">
          History and physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         A detailed history and full skin examination should be performed with particular attention to the following features:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Personal or family history of psoriasis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of exposure to potential disease triggers (eg, recent systemic glucocorticoid therapy, abrupt withdrawal of antipsoriatic medications, or infection)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Coexistence of other physical features of psoriasis (psoriatic plaques, arthralgias, or psoriatic nail disease)
        </p>
        <p>
        </p>
        <p>
         When present, these features support a diagnosis of erythrodermic psoriasis; however, their absence does not exclude the diagnosis. Scale and exfoliation are common associated physical features. Pustules may or may not be present.
        </p>
        <p>
         Features that suggest other causes of erythroderma are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/13659.html" rel="external">
          "Erythroderma in adults", section on 'Physical examination'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H682172508">
         <span class="h2">
          Skin biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Performance of a skin biopsy is generally indicated. Skin biopsies can aid in excluding other causes of erythroderma and are often helpful in establishing a diagnosis of erythrodermic psoriasis in challenging cases. Features characteristic of psoriasis often are present.
        </p>
        <p>
         In a retrospective review of biopsies obtained from 45 patients diagnosed with erythrodermic psoriasis, biopsies from 40 patients (88 percent) had histologic features consistent with psoriasis [
         <a href="#rid29">
          29
         </a>
         ]. Histologic features of early psoriasis (eg, slight epidermal hyperplasia with a reduced or absent granular layer, focal parakeratosis, and mild spongiosis) were observed in more than one-half of patients from this study, whereas the remaining patients had features of a fully developed (eg, marked epidermal hyperplasia, total loss of the granular layer, and confluent parakeratosis) or regressing (eg, slight epidermal hyperplasia and a normal or thickened granular layer) psoriasis plaque. The most common histologic feature observed in this study was marked dilation and coiling of vessels within the papillary dermis [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13659.html" rel="external">
          "Erythroderma in adults", section on 'Skin biopsy and histopathologic examination'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2778207802">
         <span class="h2">
          Laboratory tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         While no serologic tests confirm the diagnosis of erythrodermic psoriasis, specific laboratory testing is frequently necessary to guide therapeutic management and exclude other causes of erythroderma. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/13659.html" rel="external">
          "Erythroderma in adults", section on 'Laboratory and imaging tests'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3557957731">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Distinguishing erythrodermic psoriasis from other causes of erythroderma is necessary but often challenging. The patient history, physical findings, and biopsy results aid in narrowing the differential diagnosis  (
         <a class="graphic graphic_table graphicRef87714 graphicRef87724" href="/z/d/graphic/87714.html" rel="external">
          table 1A-B
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/13659.html" rel="external">
          "Erythroderma in adults", section on 'Etiology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13659.html" rel="external">
          "Erythroderma in adults", section on 'Determining the underlying cause'
         </a>
         .)
        </p>
        <p>
         The exacerbation of a pre-existing skin disease is the most common etiology of erythroderma, accounting for more than one-half of all cases [
         <a href="#rid30">
          30,31
         </a>
         ]. Psoriasis, atopic dermatitis, and seborrheic dermatitis are the most common associated cutaneous diseases. Knowledge of the clinical features prior to the onset of erythroderma is often helpful for diagnosis. Features suggestive of atopic dermatitis include an early age of onset, strong association with allergic rhinitis and asthma, prominent involvement of flexural surfaces, and disease worsening triggered by xerosis. Seborrheic dermatitis is typically characterized by dry or greasy flakes of skin, which involve the scalp, eyebrows, glabella, or external ear. (See
         <a class="medical medical_review" href="/z/d/html/1729.html" rel="external">
          "Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13669.html" rel="external">
          "Seborrheic dermatitis in adolescents and adults"
         </a>
         .)
        </p>
        <p>
         Adverse drug reactions are another common cause of erythroderma, accounting for approximately 20 percent of patients presenting with erythroderma  (
         <a class="graphic graphic_table graphicRef88412" href="/z/d/graphic/88412.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid31">
          31
         </a>
         ]. Examples of other causes of erythroderma in the differential diagnosis of erythrodermic psoriasis include pityriasis rubra pilaris, cutaneous T cell lymphoma, paraneoplastic syndrome, graft-versus-host disease in patients with a history of allogenic bone marrow transplantation, immunobullous disorders, and infections. Erythroderma may also be idiopathic.
        </p>
        <p>
         A list of causes of erythroderma is provided in a table  (
         <a class="graphic graphic_table graphicRef87714" href="/z/d/graphic/87714.html" rel="external">
          table 1A
         </a>
         ). The approach to determining the underlying cause of erythroderma is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/13659.html" rel="external">
          "Erythroderma in adults", section on 'Determining the underlying cause'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3159093775">
         <span class="h1">
          COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Potential complications of erythrodermic psoriasis include hemodynamic, thermoregulatory, and metabolic disturbances; electrolyte imbalances; infection; and acute respiratory distress syndrome:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemodynamic, metabolic, and thermoregulatory disturbances
         </strong>
         — Erythroderma is the result of increased blood flow to the skin and cutaneous vasodilation, which account for the red appearance and warmth of the skin, respectively. This shunting of blood to the skin results in increased cardiac output and may lead to complications, such as peripheral edema, high-output cardiac failure, shock, or acute renal failure [
         <a href="#rid32">
          32,33
         </a>
         ]. In addition, vasodilation and increased skin perfusion lead to fluid loss and subsequent electrolyte imbalances. Increased protein loss due to exfoliation of the skin has also been described [
         <a href="#rid34">
          34
         </a>
         ], which may lead to hypoalbuminemia and contribute to the development of peripheral edema.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with erythrodermic psoriasis also exhibit impaired thermoregulation and increased metabolic demands due to the rapid proliferation of epidermal cells [
         <a href="#rid35">
          35
         </a>
         ]. The inability to properly regulate the body's temperature results in increased water loss and may lead to electrolyte abnormalities.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection
         </strong>
         — Due to its exfoliative effect on large amounts of skin, erythrodermic psoriasis is associated with a defective skin barrier and increased portals for infection. Erythrodermic psoriasis patients are highly susceptible to skin infections, particularly staphylococcal septicemia [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute respiratory distress syndrome (ARDS)
         </strong>
         — Several reports suggest that erythrodermic psoriasis can be complicated by ARDS [
         <a href="#rid33">
          33,37,38
         </a>
         ]. The exact etiology of this complication is not known.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2941314812">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Due to a paucity of high-quality studies, there is no consensus on the best treatment algorithm for erythrodermic psoriasis. Recommendations for management are primarily based upon small uncontrolled studies, case series, case reports, and the recommendations of psoriasis experts [
         <a href="#rid11">
          11,27
         </a>
         ]. In general, management should involve:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A pretreatment evaluation for disease complications and triggers
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Supportive care
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prompt initiation of systemic antipsoriasis therapy
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2054500688">
         <span class="h2">
          Pretreatment evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pretreatment evaluation should include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vital signs, complete skin examination, and physical examination
         </strong>
         (to assess for signs of hemodynamic instability or infection)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complete blood count with differential
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Comprehensive
         </strong>
         <strong>
          metabolic panel
         </strong>
         (to assess fluid and electrolyte status and assess liver and kidney function)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Viral and/or microbiologic studies
         </strong>
         (to rule out active infections in patients with suggestive clinical findings)
        </p>
        <p>
        </p>
        <p>
         The need for additional testing is determined based upon these clinical and laboratory findings and any baseline laboratory tests required for the selected psoriasis therapy.
        </p>
        <p>
         The pretreatment evaluation should also include an assessment for potential causative drugs (see
         <a class="local">
          'Risk factors'
         </a>
         above). Triggering drugs should be discontinued whenever feasible. In particular, discontinuation of systemic glucocorticoids can be challenging, as both the administration and withdrawal of systemic glucocorticoids can trigger erythrodermic psoriasis. A common approach is a very slow taper of the systemic glucocorticoid while the patient is receiving systemic psoriasis therapy. (See
         <a class="local">
          'Systemic psoriasis therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1362709506">
         <span class="h2">
          Supportive care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with erythrodermic psoriasis require hospitalization for close clinical monitoring, replacement of fluids and electrolytes, and assistance with skin care. The decision to hospitalize is based upon disease severity and the presence of complications. Hemodynamically stable patients without rapidly progressing skin disease, significant fluid and electrolyte abnormalities, or concomitant infection are candidates for outpatient therapy provided they have adequate support at home for skin care, can return for frequent follow-up, and are in close proximity to a medical facility capable of managing erythrodermic patients. Patients with severe disease may require admission to the intensive care unit and often benefit from burn unit care where available.
        </p>
        <p>
         Supportive measures useful for the management of these patients include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring of body temperature and hemodynamic status
         </strong>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fluid and electrolyte replacement as needed
         </strong>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nutritional support
         </strong>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of associated infections
         </strong>
        </p>
        <p>
        </p>
        <p>
         Skin-directed interventions that may improve skin discomfort and pruritus include [
         <a href="#rid11">
          11
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Wet dressings
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Skin moisturization
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oatmeal baths
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical corticosteroids
         </strong>
         (medium-potency topical corticosteroids for trunk and extremities, low-potency topical corticosteroids for facial and intertriginous areas)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1085426222">
         <span class="h2">
          Systemic psoriasis therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initiation of a systemic antipsoriatic drug is essential for attaining disease control.
        </p>
        <p class="headingAnchor" id="H3418264919">
         <span class="h3">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antipsoriasis therapy should be initiated promptly. The most common drugs prescribed are
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         . Data on the comparative efficacy of these agents are lacking; therefore, factors such as the severity of disease, patient comorbidities, and drug availability influence the selection of treatment.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          Cyclosporine
         </a>
         is widely accepted as the treatment of choice for acute erythrodermic psoriasis based upon high efficacy, rapid onset of action, wide availability, and ease of administration. Patients with pre-existing renal disease or hypertension are less favorable candidates for cyclosporine therapy given the potential for cyclosporine-induced nephrotoxicity and hypertension. (See
         <a class="local">
          'Cyclosporine'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          Infliximab
         </a>
         also has a rapid onset of action and is an accepted alternative to
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         for acute erythrodermic psoriasis. Downsides of infliximab include the requirement for intravenous infusion and the high cost of this therapy. (See
         <a class="local">
          'Infliximab'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          Acitretin
         </a>
         and
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         can be effective for erythrodermic psoriasis but are less frequently used as initial therapy because of a slower onset of action compared with
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         and
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         . Initial treatment with these agents is primarily reserved for patients with contraindications to cyclosporine and infliximab or with subacute disease presentations [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="local">
          'Acitretin'
         </a>
         below and
         <a class="local">
          'Methotrexate'
         </a>
         below.)
        </p>
        <p>
         Once disease control is achieved, patients treated with
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         or
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         are generally transitioned to other therapies, such as
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , or subcutaneously administered biologic therapies. Of note, limiting the duration of cyclosporine therapy to less than one year is recommended because of risk for cyclosporine-induced nephrotoxicity. Patients who initially received acitretin or methotrexate and achieved remission with these drugs can have the dose tapered to the lowest dose necessary to maintain improvement.
        </p>
        <p class="headingAnchor" id="H669457019">
         <span class="h3">
          First-line therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          Cyclosporine
         </a>
         and
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         are the preferred first-line therapies for erythrodermic psoriasis. However, data on the efficacy of these therapies are limited.
        </p>
        <p class="headingAnchor" id="H978657940">
         <span class="h4">
          Cyclosporine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oral
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         may lead to significant improvement within the first few weeks of treatment:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – In an uncontrolled study of 33 adults with erythrodermic psoriasis given
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         (maximum initial dose of 5 mg/kg per day), complete remission (total disappearance of erythema and desquamation) occurred within one year in 22 patients (67 percent), with a median time to remission of two to four months [
         <a href="#rid39">
          39
         </a>
         ]. An additional 27 percent of patients achieved marked improvement, with at least a 70 percent reduction in the involved skin area compared with baseline.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          Cyclosporine
         </a>
         is given orally in doses of 3 to 5 mg/kg per day. For patients with severe disease, 5 mg/kg per day typically is given as initial treatment. Significant improvement often occurs within the first month [
         <a href="#rid39">
          39
         </a>
         ]. Once remission is achieved, the dose is tapered as tolerated over a few months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Risk for cyclosporine-induced nephrotoxicity limits the duration of treatment. Treatment with
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         should not exceed one year and should be discontinued after three to four months in patients unresponsive to a dose of 5 mg/kg per day [
         <a href="#rid11">
          11,40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to nephrotoxicity, important adverse effects of
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         include drug interactions, uncontrolled hypertension, and increased risk for infections and malignancy. Use of cyclosporine in patients with pre-existing renal disease or hypertension should be considered carefully. Such patients may benefit from alternative therapies. Adverse effects of cyclosporine are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">
          "Pharmacology of cyclosporine and tacrolimus", section on 'Side effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">
          "Cyclosporine and tacrolimus nephrotoxicity"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Baseline and periodic monitoring of blood pressure and laboratory tests is indicated for
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         therapy. For additional information, refer to the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included within UpToDate.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1225721311">
         <span class="h4">
          Infliximab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          Infliximab
         </a>
         is a common alternative to
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         for acute erythrodermic psoriasis [
         <a href="#rid11">
          11,27
         </a>
         ]. Like cyclosporine, infliximab has a rapid onset of action:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – In a retrospective study that included 24 treatment courses of
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         in 20 patients with erythrodermic psoriasis, 50 percent of patients given infliximab achieved at least a 50 percent improvement in either the Psoriasis Area and Severity Index score or body surface area involvement by four weeks [
         <a href="#rid41">
          41
         </a>
         ]. Good responses to infliximab have also been documented in a small uncontrolled study and case reports [
         <a href="#rid42">
          42-45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          Infliximab
         </a>
         is given as the standard regimen recommended for psoriasis (5 mg/kg at zero, two, and six weeks, followed by 5 mg/kg every eight weeks). Marked improvement can occur within the first several weeks of treatment. If there is no treatment response observed within four to six weeks, significant benefit may be less likely to occur. In this scenario, we would transition the patient to
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         or another treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Potential serious side effects of
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         include infusion reactions, increased risk for infection, exacerbations of heart failure, demyelinating disease, and malignancy. Infliximab is contraindicated in patients with active infections and should be used cautiously in patients with neurologic disorders (eg, multiple sclerosis), heart failure, or a history of malignancy. Screening for tuberculosis is recommended prior to infliximab treatment. The adverse effects of infliximab are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7970.html" rel="external">
          "Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1578478868">
         <span class="h3">
          Alternative first-line therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          Acitretin
         </a>
         and
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         may be effective for erythrodermic psoriasis but exhibit a slower onset of action compared with
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         and
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         . Thus, initial treatment with these agents is typically reserved for patients who cannot be treated with cyclosporine or infliximab or who have subacute disease presentations.
        </p>
        <p class="headingAnchor" id="H4192862366">
         <span class="h4">
          Acitretin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          Acitretin
         </a>
         for erythrodermic psoriasis is typically given in doses of 25 to 50 mg per day. The maximal effect of acitretin often is not evident for three to six months [
         <a href="#rid40">
          40
         </a>
         ]. If at least partial improvement does not occur within three months, we discontinue treatment.
        </p>
        <p>
         Although
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         is a common treatment for psoriasis, data on efficacy for the erythrodermic variant are limited. In a 1988 review of data from 12 open or double-blind clinical studies evaluating acitretin for psoriasis, improvement assessed as at least marked or good occurred in five of the six erythrodermic patients treated with acitretin [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          Acitretin
         </a>
         can cause hyperlipidemia and hepatotoxicity, and some patients are unable to tolerate the drug due to side effects such as paresthesias, arthralgias, cheilitis, and xerostomia. Acitretin is teratogenic and should be avoided in pregnant women and females of child-bearing potential who intend to become pregnant within three years after discontinuation of treatment. For additional information on side effects and monitoring, refer to the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included within UpToDate.
        </p>
        <p class="headingAnchor" id="H4153229371">
         <span class="h4">
          Methotrexate
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          Methotrexate
         </a>
         is typically given on a weekly basis; adults with erythrodermic psoriasis are typically treated with a single weekly dose of 7.5 to 25 mg per day.
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          Folic acid
         </a>
         supplementation (1 mg per day) should be given in conjunction with methotrexate therapy.
        </p>
        <p>
         Initial signs of therapeutic benefit are often evident within the first four weeks of treatment. If there are no signs of response within four to six weeks, we discontinue
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         treatment.
        </p>
        <p>
         Similar to
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         , efficacy data for erythrodermic psoriasis are limited. In a retrospective review of 157 psoriasis patients treated with
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , a response rated as a "moderate" or "good" clinical response was observed in 34 of 36 erythrodermic patients [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Gastrointestinal distress is a common side effect of
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         . Potential serious adverse effects of methotrexate include hepatotoxicity, myelosuppression, and pulmonary toxicity. Methotrexate is teratogenic and is contraindicated during pregnancy. The drug is also contraindicated in patients with active infections, malignancy, bone marrow suppression, or pre-existing kidney or liver disease. Close monitoring for hematologic and hepatic side effects is essential during methotrexate therapy. For additional information on side effects and monitoring, refer to the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included within UpToDate.
        </p>
        <p class="headingAnchor" id="H3888126888">
         <span class="h4">
          Other therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited data suggest that
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         ,
         <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">
          adalimumab
         </a>
         , and other biologic therapies can be effective for erythrodermic psoriasis. In a multicenter, retrospective review of 24 erythrodermic psoriasis patients treated with various tumor necrosis factor (TNF)-alpha inhibitors, the efficacy of etanercept and adalimumab was comparable with
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         [
         <a href="#rid41">
          41
         </a>
         ]. However, the onset of action of these agents is slower than for
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         or infliximab [
         <a href="#rid27">
          27,48
         </a>
         ], making them less preferable therapies for erythrodermic psoriasis.
        </p>
        <p>
         Small, open-label studies and case reports provide preliminary support for the use of newer biologic medications for the treatment of erythrodermic psoriasis, including
         <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">
          ustekinumab
         </a>
         [
         <a href="#rid49">
          49
         </a>
         ],
         <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">
          ixekizumab
         </a>
         [
         <a href="#rid50">
          50-52
         </a>
         ],
         <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">
          secukinumab
         </a>
         [
         <a href="#rid53">
          53,54
         </a>
         ],
         <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">
          guselkumab
         </a>
         [
         <a href="#rid55">
          55
         </a>
         ],
         <a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">
          brodalumab
         </a>
         [
         <a href="#rid56">
          56
         </a>
         ],
         <a class="drug drug_general" data-topicid="121112" href="/z/d/drug information/121112.html" rel="external">
          risankizumab
         </a>
         [
         <a href="#rid57">
          57
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">
          golimumab
         </a>
         [
         <a href="#rid58">
          58
         </a>
         ], as well as the small molecule drug
         <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">
          apremilast
         </a>
         [
         <a href="#rid59">
          59-61
         </a>
         ]. While these therapies represent a group of medications likely to be effective in the treatment of erythrodermic psoriasis, subsequent, larger studies are necessary prior to a recommendation for the routine use of these therapies. That said, the rapid onset of interleukin (IL) 17 inhibitors and their apparent efficacy in open-label studies of patients with generalized pustular psoriasis make them attractive alternatives to anti-TNF or anti-IL-12/23 inhibitors. (See
         <a class="medical medical_review" href="/z/d/html/93554.html" rel="external">
          "Pustular psoriasis: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2352832768">
         <span class="h3">
          Severe, refractory disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Combinations of systemic therapies may be appropriate in severe or refractory cases of erythrodermic psoriasis (eg,
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         with
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         or
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         ). However, evidence for this approach is based largely on case reports or small case series [
         <a href="#rid44">
          44,62
         </a>
         ].
        </p>
        <p>
         The potential benefit of wet dressings with mid-potency topical corticosteroids (eg,
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          triamcinolone
         </a>
         0.1% cream) should not be discounted in patients with severe disease. Use in combination with systemic treatments aids in the management of patient symptoms and may promote disease resolution. (See
         <a class="local">
          'Supportive care'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2074002117">
         <span class="h2">
          Contraindicated therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of systemic glucocorticoids for erythrodermic psoriasis is strongly discouraged due to the ability of systemic glucocorticoids to trigger severe psoriasis flares. Phototherapy is also generally avoided in erythrodermic patients given the photosensitivity of these patients, though this recommendation is not absolute. (See
         <a class="local">
          'HIV-infected patients'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4073363061">
         <span class="h2">
          Special population
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to the treatment of erythrodermic psoriasis differs in HIV-infected individuals.
        </p>
        <p class="headingAnchor" id="H1374196356">
         <span class="h3">
          HIV-infected patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients infected with HIV are at increased risk for psoriasis, including less common variants like erythrodermic psoriasis [
         <a href="#rid63">
          63
         </a>
         ]. HIV-associated psoriasis tends to follow a more severe disease course and is also frequently refractory to conventional antipsoriatic therapies, which primarily target the T cell-mediated immune response. Therefore, the management of erythrodermic psoriasis in HIV-infected patients represents a challenging clinical scenario based on their relative immunosuppression, susceptibility for infections, and severity of symptoms.
        </p>
        <p>
         We agree with the Medical Board of the National Psoriasis Foundation, which recommends antiretroviral therapy or ultraviolet (UV) phototherapy as first-line treatments for erythrodermic psoriasis in HIV-positive patients [
         <a href="#rid64">
          64
         </a>
         ]. The potential benefit of antiretroviral therapy for the treatment of erythrodermic psoriasis is highlighted in a report of a patient who experienced rapid clearing of his clinical symptoms within two weeks of initiating antiretroviral therapy despite previous failure to respond to
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         , systemic glucocorticoids, and TNF-alpha inhibitors [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          Acitretin
         </a>
         is recommended as second-line treatment. The use of other conventional psoriasis medications, such as
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , and TNF-alpha inhibitors, is based on limited clinical evidence, and they should be used with caution due to the increased risk of opportunistic infections and bone marrow toxicity [
         <a href="#rid66">
          66,67
         </a>
         ]. (See
         <a class="local">
          'Acitretin'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/15279.html" rel="external">
          "Treatment selection for moderate to severe plaque psoriasis in special populations", section on 'HIV infection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2670135464">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Overall, the majority of erythrodermic psoriasis patients respond to one or more available treatment options. However, prognostic data for this condition are deficient and highly variable, with mortality rates ranging anywhere from 9 to 64 percent [
         <a href="#rid3">
          3,28
         </a>
         ]. Most deaths associated with erythrodermic psoriasis are attributed to bacterial infections, such as pneumonia or staphylococcal septicemia [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H56209720">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112498.html" rel="external">
          "Society guideline links: Psoriasis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1072321554">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease overview
         </strong>
         – Erythrodermic psoriasis is a potentially life-threatening, rare subtype of psoriasis characterized by erythema involving more than 75 percent of the body surface area and the presence of scaling, exfoliation/desquamation, and/or pustules of the skin  (
         <a class="graphic graphic_picture graphicRef111552 graphicRef111553 graphicRef111554" href="/z/d/graphic/111552.html" rel="external">
          picture 1A-C
         </a>
         ). Systemic signs and symptoms, including fever, chills, malaise, tachycardia, arthralgias, eosinophilia, anemia, lymphadenopathy, and photosensitivity, are commonly associated with erythrodermic psoriasis. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – More than one-half of all cases of erythrodermic psoriasis are attributed to the exacerbation of pre-existing psoriasis. Important triggers include medications (eg, the withdrawal of oral or topical corticosteroids and the discontinuation or abrupt withdrawal of antipsoriatic therapies), infections, alcohol consumption, and stress. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Differentiating erythrodermic psoriasis from other causes of erythroderma is essential but frequently challenging. The diagnosis is made based upon the recognition of features of psoriasis in the patient history, physical examination, and/or skin biopsy and the absence of features indicative of other causes of erythroderma. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications
         </strong>
         – Complications of erythrodermic psoriasis include hemodynamic and metabolic disturbances, increased metabolic requirements, a defective skin barrier, impaired thermoregulation, acute respiratory distress syndrome (ARDS), and susceptibility to skin infections, specifically staphylococcal septicemia. (See
         <a class="local">
          'Complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supportive care
         </strong>
         – Inpatient hospitalization may be necessary for close clinical evaluation, including hemodynamic monitoring, replacement of fluids and electrolytes, and assistance with the application of wet dressings. Patients with severe disease may require admission to the intensive care unit and often benefit from burn unit care where available. (See
         <a class="local">
          'Supportive care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Treatment guidelines for erythrodermic psoriasis are based on small uncontrolled studies, case series, case reports, and expert opinion. Factors such as severity of disease, patient comorbidities, and drug availability influence the selection of treatment (see
         <a class="local">
          'Systemic psoriasis therapy'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          First-line therapy
         </strong>
         – We suggest
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         or
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         as first-line therapy for erythrodermic psoriasis based upon the rapid onset of action of these therapies (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          Acitretin
         </a>
         and
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         are also first-line treatment options, though a slower onset of action makes them less preferable agents. (See
         <a class="local">
          'Systemic psoriasis therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other therapies
         </strong>
         – Additional treatments that may be effective include other tumor necrosis factor (TNF)-alpha inhibitors (eg,
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         ,
         <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">
          golimumab
         </a>
         , and
         <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">
          adalimumab
         </a>
         ), other biologic medications (eg, interleukin [IL] 12/23, IL-17A, IL-17 receptor, and IL-23 inhibitors), and antipsoriatic small molecules (eg,
         <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">
          apremilast
         </a>
         ) used in the treatment of other psoriasis subtypes. (See
         <a class="local">
          'Other therapies'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol 2014; 70:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lebwohl M. Psoriasis. Lancet 2003; 361:1197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyd AS, Menter A. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol 1989; 21:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ye F, Gui X, Wu C, et al. Severity evaluation and prognostic factors in erythrodermic psoriasis. Eur J Dermatol 2018; 28:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xing X, Liang Y, Sarkar MK, et al. IL-17 Responses Are the Dominant Inflammatory Signal Linking Inverse, Erythrodermic, and Chronic Plaque Psoriasis. J Invest Dermatol 2016; 136:2498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang P, Chen HX, Duan YQ, et al. Analysis of Th1/Th2 response pattern for erythrodermic psoriasis. J Huazhong Univ Sci Technolog Med Sci 2014; 34:596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdallah MA, Abdel-Hamid MF, Kotb AM, Mabrouk EA. Serum interferon-gamma is a psoriasis severity and prognostic marker. Cutis 2009; 84:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo Y, Chiu HY, Tsai TF. Clinical Features and Genetic Polymorphism in Chinese Patients with Erythrodermic Psoriasis in a Single Dermatologic Clinic. Mol Diagn Ther 2020; 24:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Signa S, Campione E, Rusmini M, et al. Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab. Pediatr Rheumatol Online J 2019; 17:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moy AP, Murali M, Kroshinsky D, et al. Immunologic Overlap of Helper T-Cell Subtypes 17 and 22 in Erythrodermic Psoriasis and Atopic Dermatitis. JAMA Dermatol 2015; 151:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenbach M, Hsu S, Korman NJ, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 62:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol 2012; 67:e179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goiriz R, Daudén E, Pérez-Gala S, et al. Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers. Clin Exp Dermatol 2007; 32:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esposito M, Saraceno R, Schipani C, et al. Trimethoprim-sulfamethoxazole induced erythrodermic psoriasis. J Infect 2008; 57:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cox NH, Gordon PM, Dodd H. Generalized pustular and erythrodermic psoriasis associated with bupropion treatment. Br J Dermatol 2002; 146:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemmenmeier E, Gaus B, Schmid P, Hoffmann M. A case of erythrodermia from exacerbated psoriasis vulgaris due to treatment of acute hepatitis C. BMC Dermatol 2016; 16:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morar N, Willis-Owen SA, Maurer T, Bunker CB. HIV-associated psoriasis: pathogenesis, clinical features, and management. Lancet Infect Dis 2010; 10:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Behrangi E, Sadeghzadeh-Bazargan A, Salimi N, et al. Erythrodermic flare-up of psoriasis with COVID-19 infection: A report of two cases and a comprehensive review of literature focusing on the mutual effect of psoriasis and COVID-19 on each other along with the special challenges of the pandemic. Clin Case Rep 2022; 10:e05722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nia AM, Silva MM, Spaude J, Gonzalez-Fraga JD. Erythrodermic psoriasis eruption associated with SARS-CoV-2 vaccination. Dermatol Ther 2022; 35:e15380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tran TB, Pham NTU, Phan HN, Nguyen HT. Generalized erythrodermic psoriasis triggered by vaccination against severe acute respiratory syndrome Coronavirus 2. Dermatol Ther 2022; 35:e15464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saraceno R, Talamonti M, Galluzzo M, et al. Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases. Case Rep Dermatol 2013; 5:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burden AD, Muston H, Beck MH. Intolerance and contact allergy to tar and dithranol in psoriasis. Contact Dermatitis 1994; 31:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagliaro JA, Jones SK. Recurrent erythrodermic psoriasis in a thiuram-allergic patient due to contact with nurses' rubber gloves. Br J Dermatol 1999; 140:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Preiss JC, Zouboulis CC, Zeitz M, Duchmann R. [Severe erythrodermic psoriasis in a patient with 22q11 deletion syndrome]. Med Klin (Munich) 2005; 100:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guerreiro de Moura CA, de Assis LH, Góes P, et al. A Case of Acute Generalized Pustular Psoriasis of von Zumbusch Triggered by Hypocalcemia. Case Rep Dermatol 2015; 7:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart AF, Battaglini-Sabetta J, Millstone L. Hypocalcemia-induced pustular psoriasis of von Zumbusch. New experience with an old syndrome. Ann Intern Med 1984; 100:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strober BE, Clay Cather J, Cohen D, et al. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. Dermatol Ther (Heidelb) 2012; 2:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicolis GD, Helwig EB. Exfoliative dermatitis. A clinicopathologic study of 135 cases. Arch Dermatol 1973; 108:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomasini C, Aloi F, Solaroli C, Pippione M. Psoriatic erythroderma: a histopathologic study of forty-five patients. Dermatology 1997; 194:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akhyani M, Ghodsi ZS, Toosi S, Dabbaghian H. Erythroderma: a clinical study of 97 cases. BMC Dermatol 2005; 5:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sigurdsson V, Toonstra J, Hezemans-Boer M, van Vloten WA. Erythroderma. A clinical and follow-up study of 102 patients, with special emphasis on survival. J Am Acad Dermatol 1996; 35:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SHUSTER S. High-output cardiac failure from skin disease. Lancet 1963; 1:1338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voigt GC, Kronthal HL, Crounse RG. Cardiac output in erythrodermic skin disease. Am Heart J 1966; 72:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanthraj GR, Srinivas CR, Devi PU, et al. Quantitative estimation and recommendations for supplementation of protein lost through scaling in exfoliative dermatitis. Int J Dermatol 1999; 38:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           FOX RH, SHUSTER S, WILLIAMS R, et al. CARDIOVASCULAR, METABOLIC, AND THERMOREGULATORY DISTURBANCES IN PATIENTS WITH ERYTHRODERMIC SKIN DISEASES. Br Med J 1965; 1:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green MS, Prystowsky JH, Cohen SR, et al. Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol 1996; 34:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGregor JM, Barker JN, MacDonald DM. Pulmonary capillary leak syndrome complicating generalized pustular psoriasis: possible role of cytokines. Br J Dermatol 1991; 125:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadeh JS, Rudikoff D, Gordon ML, et al. Pustular and erythrodermic psoriasis complicated by acute respiratory distress syndrome. Arch Dermatol 1997; 133:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Management of erythrodermic psoriasis with low-dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO). Dermatology 1993; 187 Suppl 1:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viguier M, Pagès C, Aubin F, et al. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Br J Dermatol 2012; 167:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis TG, Tuchinda C, Lim HW, Wong HK. Life-threatening pustular and erythrodermic psoriasis responding to infliximab. J Drugs Dermatol 2006; 5:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rongioletti F, Borenstein M, Kirsner R, Kerdel F. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. J Dermatolog Treat 2003; 14:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takahashi MD, Castro LG, Romiti R. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. Br J Dermatol 2007; 157:828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poulalhon N, Begon E, Lebbé C, et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol 2007; 156:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geiger JM, Czarnetzki BM. Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies. Dermatologica 1988; 176:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muchenberger S, Schöpf E, Simon JC. The combination of oral acitretin and bath PUVA for the treatment of severe psoriasis. Br J Dermatol 1997; 137:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nast A, Sporbeck B, Rosumeck S, et al. Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action. J Invest Dermatol 2013; 133:1963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pescitelli L, Dini V, Gisondi P, et al. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis. J Dermatol Sci 2015; 78:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saeki H, Nakagawa H, Ishii T, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol 2015; 29:1148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Egawa G, Honda T, Kabashima K. Long-term efficacy of ixekizumab in erythrodermic and generalized pustular psoriasis patients. J Eur Acad Dermatol Venereol 2019; 33:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vinaixa Aranzazu A, Morillas-Lahuerta V, Blanco De Tord M, Carrascosa Carrillo JM. Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumab-tremelimumab in a cancer patient. Eur J Dermatol 2021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weng HJ, Wang TS, Tsai TF. Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series. Br J Dermatol 2018; 178:1439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Damiani G, Pacifico A, Russo F, et al. Use of Secukinumab in a Cohort of Erythrodermic Psoriatic Patients: A Pilot Study. J Clin Med 2019; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol 2018; 45:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamasaki K, Nakagawa H, Kubo Y, et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol 2017; 176:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khatri A, Eckert D, Oberoi R, et al. Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis. J Clin Pharmacol 2019; 59:1656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee WK, Kim GW, Cho HH, et al. Erythrodermic Psoriasis Treated with Golimumab: A Case Report. Ann Dermatol 2015; 27:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krishnamoorthy G, Kotecha A, Pimentel J. Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy. BMJ Case Rep 2019; 12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Megna M, Ocampo-Garza SS, Fabbrocini G, et al. A case of erythrodermic psoriasis successfully treated with apremilast. Dermatol Ther 2022; 35:e15204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gioe OA, Savoie C, Grieshaber EB, Hilton DC. Treatment of erythrodermic psoriasis with apremilast. JAAD Case Rep 2021; 11:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heikkilä H, Ranki A, Cajanus S, Karvonen SL. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis. Arch Dermatol 2005; 141:1607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mallon E, Bunker CB. HIV-associated psoriasis. AIDS Patient Care STDS 2000; 14:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menon K, Van Voorhees AS, Bebo BF Jr, et al. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 62:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiricozzi A, Saraceno R, Cannizzaro MV, et al. Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir). Dermatology 2012; 225:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masson C, Chennebault JM, Leclech C. Is HIV infection contraindication to the use of methotrexate in psoriatic arthritis? J Rheumatol 1995; 22:2191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maurer TA, Zackheim HS, Tuffanelli L, Berger TG. The use of methotrexate for treatment of psoriasis in patients with HIV infection. J Am Acad Dermatol 1994; 31:372.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 110151 Version 8.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24388724" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Psoriasis prevalence among adults in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12686053" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Psoriasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2530253" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30530426" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Severity evaluation and prognostic factors in erythrodermic psoriasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27448749" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : IL-17 Responses Are the Dominant Inflammatory Signal Linking Inverse, Erythrodermic, and Chronic Plaque Psoriasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25135734" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Analysis of Th1/Th2 response pattern for erythrodermic psoriasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19842576" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Serum interferon-gamma is a psoriasis severity and prognostic marker.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31820331" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Clinical Features and Genetic Polymorphism in Chinese Patients with Erythrodermic Psoriasis in a Single Dermatologic Clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31286971" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25760640" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Immunologic Overlap of Helper T-Cell Subtypes 17 and 22 in Erythrodermic Psoriasis and Atopic Dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19665821" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21752492" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-αinhibitors: the Mayo Clinic experience, 1998 to 2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17176269" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18499260" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Trimethoprim-sulfamethoxazole induced erythrodermic psoriasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12072078" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Generalized pustular and erythrodermic psoriasis associated with bupropion treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27230122" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A case of erythrodermia from exacerbated psoriasis vulgaris due to treatment of acute hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20610329" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : HIV-associated psoriasis: pathogenesis, clinical features, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35474976" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Erythrodermic flare-up of psoriasis with COVID-19 infection: A report of two cases and a comprehensive review of literature focusing on the mutual effect of psoriasis and COVID-19 on each other along with the special challenges of the pandemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35170153" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Erythrodermic psoriasis eruption associated with SARS-CoV-2 vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35306720" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Generalized erythrodermic psoriasis triggered by vaccination against severe acute respiratory syndrome Coronavirus 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24163658" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7821017" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Intolerance and contact allergy to tar and dithranol in psoriasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10233815" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Recurrent erythrodermic psoriasis in a thiuram-allergic patient due to contact with nurses' rubber gloves.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15902381" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : [Severe erythrodermic psoriasis in a patient with 22q11 deletion syndrome].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26955330" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : A Case of Acute Generalized Pustular Psoriasis of von Zumbusch Triggered by Hypocalcemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6546844" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Hypocalcemia-induced pustular psoriasis of von Zumbusch. New experience with an old syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23205325" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4271796" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Exfoliative dermatitis. A clinicopathologic study of 135 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9094455" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Psoriatic erythroderma: a histopathologic study of forty-five patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15882451" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Erythroderma: a clinical study of 97 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8682964" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Erythroderma. A clinical and follow-up study of 102 patients, with special emphasis on survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13988813" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : High-output cardiac failure from skin disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4224242" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Cardiac output in erythrodermic skin disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10192155" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Quantitative estimation and recommendations for supplementation of protein lost through scaling in exfoliative dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14245176" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : CARDIOVASCULAR, METABOLIC, AND THERMOREGULATORY DISTURBANCES IN PATIENTS WITH ERYTHRODERMIC SKIN DISEASES.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8621827" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Infectious complications of erythrodermic psoriasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1751356" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Pulmonary capillary leak syndrome complicating generalized pustular psoriasis: possible role of cytokines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9197829" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Pustular and erythrodermic psoriasis complicated by acute respiratory distress syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8369577" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Management of erythrodermic psoriasis with low-dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19493586" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22413927" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16774108" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Life-threatening pustular and erythrodermic psoriasis responding to infliximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14660268" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17711530" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17223874" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2967779" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9390336" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The combination of oral acitretin and bath PUVA for the treatment of severe psoriasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23426133" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25681953" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25355284" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30746797" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Long-term efficacy of ixekizumab in erythrodermic and generalized pustular psoriasis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34463279" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumab-tremelimumab in a cancer patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29265175" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31159169" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Use of Secukinumab in a Cohort of Erythrodermic Psoriatic Patients: A Pilot Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29569397" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27106510" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31257614" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26273164" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Erythrodermic Psoriasis Treated with Golimumab: A Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30709830" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34783133" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : A case of erythrodermic psoriasis successfully treated with apremilast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33898682" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Treatment of erythrodermic psoriasis with apremilast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16365275" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10833810" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : HIV-associated psoriasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19646777" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23295963" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8596175" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Is HIV infection contraindication to the use of methotrexate in psoriatic arthritis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8034807" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : The use of methotrexate for treatment of psoriasis in patients with HIV infection.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
